“…Several molecular studies described mutations or alterations of multiple genes and pathways in endometrial carcinosarcoma, including c-KIT, TKR, VEGF, EGFR, Her2/ neu, NTRK, PI3K/AKT/mTOR pathway, WEE1, KRAS, EXP, BRCA1/2, and other genes related to cell-cycle regulation (including homologous recombination deficiency), histone modification, and chromatin remodeling, which may all represent potential targets. [21][22][23][24][25][26][27] New molecular-targeted therapies may play a pivotal role in the treatment of endometrial carcinosarcoma, especially in the recurrence/metastatic setting, and many of these are currently being investigated in prospective clinical trials (Table 5), with the most promising therapeutic agents being immune checkpoint inhibitors, HER2 targeting agents, and WEE1 inhibitors. 104…”